Abdesselam Inès, Pepino Pauline, Troalen Thomas, Macia Michael, Ancel Patricia, Masi Brice, Fourny Natacha, Gaborit Bénédicte, Giannesini Benoît, Kober Frank, Dutour Anne, Bernard Monique
Aix-Marseille Université, CNRS, CRMBM, UMR7339, 27, Bd Jean Moulin, 13385, Marseille, France.
Aix-Marseille Université, NORT, Inserm U1062/Inra1260, 13385, Marseille, France.
J Cardiovasc Magn Reson. 2015 Nov 6;17:95. doi: 10.1186/s12968-015-0198-x.
Cardiovascular complications of obesity and diabetes are major health problems. Assessing their development, their link with ectopic fat deposition and their flexibility with therapeutic intervention is essential. The aim of this study was to longitudinally investigate cardiac alterations and ectopic fat accumulation associated with diet-induced obesity using multimodal cardiovascular magnetic resonance (CMR) in mice. The second objective was to monitor cardiac response to exendin-4 (GLP-1 receptor agonist).
Male C57BL6R mice subjected to a high fat (35 %) high sucrose (34 %) (HFHSD) or a standard diet (SD) during 4 months were explored every month with multimodal CMR to determine hepatic and myocardial triglyceride content (HTGC, MTGC) using proton MR spectroscopy, cardiac function with cine cardiac MR (CMR) and myocardial perfusion with arterial spin labeling CMR. Furthermore, mice treated with exendin-4 (30 μg/kg SC BID) after 4 months of diet were explored before and 14 days post-treatment with multimodal CMR.
HFHSD mice became significantly heavier (+33 %) and displayed glucose homeostasis impairment (1-month) as compared to SD mice, and developed early increase in HTGC (1 month, +59 %) and MTGC (2-month, +63 %). After 3 months, HFHSD mice developed cardiac dysfunction with significantly higher diastolic septum wall thickness (sWtnD) (1.28 ± 0.03 mm vs. 1.12 ± 0.03 mm) and lower cardiac index (0.45 ± 0.06 mL/min/g vs. 0.68 ± 0.07 mL/min/g, p = 0.02) compared to SD mice. A significantly lower cardiac perfusion was also observed (4 months:7.5 ± 0.8 mL/g/min vs. 10.0 ± 0.7 mL/g/min, p = 0.03). Cardiac function at 4 months was negatively correlated to both HTGC and MTGC (p < 0.05). 14-day treatment with Exendin-4 (Ex-4) dramatically reversed all these alterations in comparison with placebo-treated HFHSD. Ex-4 diminished myocardial triglyceride content (-57.8 ± 4.1 %), improved cardiac index (+38.9 ± 10.9 %) and restored myocardial perfusion (+52.8 ± 16.4 %) under isoflurane anesthesia. Interestingly, increased wall thickness and hepatic steatosis reductions were independent of weight loss and glycemia decrease in multivariate analysis (p < 0.05).
CMR longitudinal follow-up of cardiac consequences of obesity and diabetes showed early accumulation of ectopic fat in mice before the occurrence of microvascular and contractile dysfunction. This study also supports a cardioprotective effect of glucagon-like peptide-1 receptor agonist.
肥胖和糖尿病的心血管并发症是主要的健康问题。评估它们的发展、与异位脂肪沉积的联系以及治疗干预的灵活性至关重要。本研究的目的是使用多模态心血管磁共振成像(CMR)对饮食诱导肥胖的小鼠进行纵向研究,以观察心脏改变和异位脂肪堆积情况。第二个目标是监测心脏对艾塞那肽-4(胰高血糖素样肽-1受体激动剂)的反应。
雄性C57BL6R小鼠分别给予高脂肪(35%)高蔗糖(34%)(HFHSD)或标准饮食(SD)4个月,每月使用多模态CMR进行检查,通过质子磁共振波谱测定肝脏和心肌甘油三酯含量(HTGC、MTGC),通过电影心脏磁共振成像(CMR)评估心脏功能,通过动脉自旋标记CMR评估心肌灌注。此外,在饮食4个月后用艾塞那肽-4(30μg/kg皮下注射,每日两次)治疗的小鼠,在治疗前和治疗后14天进行多模态CMR检查。
与SD小鼠相比,HFHSD小鼠体重显著增加(+33%),1个月时出现葡萄糖稳态受损,HTGC(1个月时增加59%)和MTGC(2个月时增加63%)早期升高。3个月后,HFHSD小鼠出现心脏功能障碍,与SD小鼠相比,舒张期室间隔壁厚度(sWtnD)显著增加(1.28±0.03mm对1.12±0.03mm),心脏指数降低(0.45±0.06mL/min/g对0.68±0.07mL/min/g,p=0.02)。4个月时还观察到心脏灌注显著降低(7.5±0.8mL/g/min对10.0±0.7mL/g/min,p=0.03)。4个月时的心脏功能与HTGC和MTGC均呈负相关(p<0.05)。与安慰剂治疗的HFHSD小鼠相比,艾塞那肽-4(Ex-4)治疗14天显著逆转了所有这些改变。在异氟烷麻醉下,Ex-4减少了心肌甘油三酯含量(-57.8±4.1%),改善了心脏指数(+38.9±10.9%),恢复了心肌灌注(+52.8±16.4%)。有趣的是,在多变量分析中,室壁厚度增加和肝脂肪变性减轻与体重减轻和血糖降低无关(p<0.05)。
CMR对肥胖和糖尿病心脏后果的纵向随访显示,在微血管和收缩功能障碍发生之前,小鼠体内就出现了异位脂肪的早期堆积。本研究还支持胰高血糖素样肽-1受体激动剂的心脏保护作用。